- Home
- QLGN
as 12-18-2024 12:41pm EST
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CALIFORNIA |
| Market Cap: | 3.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 54.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -41.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.34 - $30.50 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Qualigen Therapeutics Inc. News
QLGN Breaking Stock News: Dive into QLGN Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
Qualigen Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price, Equity Rules
GlobeNewswire
13 days ago
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
GlobeNewswire
23 days ago
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
GlobeNewswire
a month ago
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
GlobeNewswire
2 months ago
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
GlobeNewswire
3 months ago
Qualigen Therapeutics, Inc. Announces management changes.
GlobeNewswire
3 months ago
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
GlobeNewswire
3 months ago
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Compare QLGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QLGN Qualigen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.